Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Head & Neck 1

Conditions

Carcinoma, Renal Cell 2Prostatic Neoplasms 1Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumors 1Advanced Solid Tumor 1

Interventions

pembrolizumab 47Nivolumab 34Sunitinib 18Cyclophosphamide 18Everolimus 17Ipilimumab 15cabozantinib 14pazopanib 13Bevacizumab 13fludarabine 12atezolizumab 11temsirolimus 10Magnetic Resonance Spectroscopy 10Sorafenib 9aldesleukin 8Specimen Handling 8Paclitaxel 8Sirolimus 7CTLA-4 Antigen 7Axitinib 7belzutifan 6Radiosurgery 6Oxaliplatin 6Interleukin-2 6Fluorouracil 6spartalizumab 5avelumab 5Leucovorin 5Irinotecan 5Docetaxel 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Renal Cell × sitravatinib × Clear all
NCT04518046 2024-06-05

Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

Mirati Therapeutics Inc.

Phase 1 Completed
22 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT02219711 2023-03-06

Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer

Mirati Therapeutics Inc.

Phase 1 Completed
193 enrolled
GenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡